News
BSX
67.42
-0.79%
-0.54
BofA’s US 1 List - New additions include CSCO, GS and SPGI
BofA’s US 1 List - New additions include CSCO, GS and SPGI. The newest additions to the US 1 list include Cisco Systems, Goldman Sachs Group and S&P Global. The list is a collection of BofA's best investment ideas from buy-rated stocks.
Seeking Alpha · 7h ago
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
Boston Scientific Corporation said it recalled Obsidio Embolic by issuing a correction. The FDA has identified this as a Class I recall, the most severe type of recall. Eleven incidents were reported, seven injuries, and two deaths related to this issue. The company has issued a recall for around 1,600 devices.
Benzinga · 9h ago
Boston Sci issues corrective recall for Obsidio Embolic over safety concerns
Healthcare Boston Sci issues corrective recall for Obsidio Embolic over safety concerns. FDA has received 11 incident reports related to the matter. Seven injuries and two deaths have been reported. Boston Scientific has issued a corrective recall of its embolization agent ObsidIO.
Seeking Alpha · 1d ago
UPDATE 1-FDA classifies recall of Boston Scientific device as 'most serious'
FDA classifies recall of Boston Scientific device as 'most serious' 11 incidents reported, seven injuries, and two deaths related to the issue. Device used to block blood flow during excessive bleeding or hemorrhaging. FDA says device poses a higher risk of bowel ischemia during procedures to stop gastrointestinal bleeding.
Reuters · 1d ago
FDA classifies recall of Boston Scientific device to treat hemorrhaging as 'most serious'
FDA classifies recall of Boston Scientific device to treat hemorrhaging as 'most serious' 11 incidents reported, seven injuries, and two deaths related to the device's issue, FDA says. Device used to block blood flow during excessive bleeding or hemorrhaging. Boston Scientific's BSX.N device is used to treat bleeding.
Reuters · 1d ago
FDA Says Boston Scientific Recalls Obsidio Conformable Embolic For Increased Bowel Ischemia Risk When Used For Lower GI Bleeding; Boston Scientific Recall Is A Correction, Not A Product Removal as A Class I Recall;11 Incidents Reported, Seven Injuries, And Two Deaths Related To Obsidio Embolic
Benzinga · 1d ago
FDA:11 INCIDENTS REPORTED, SEVEN INJURIES, AND TWO DEATHS RELATED TO OBSIDIO EMBOLIC
Reuters · 1d ago
3 Safe Haven Stocks to Own in an Unpredictable Market
The S&P 500 Index is down more than 4% to start April. Investors are turning to safe havens like gold. PepsiCo, Inc. (PEP) and Boston Scientific Corporation (BSX) are on our list of safe haven stocks. The two companies are defensive stocks that could weather any economic turmoil.
Barchart · 1d ago
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years
Boston Scientific has outperformed the market over the past 10 years by 7.04% on an annualized basis. The company has an average annual return of 17.43%. If an investor bought $1000 of BSX stock 10 years ago, it would be worth $4,998.54 today.
Benzinga · 2d ago
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
NASDAQ · 2d ago
After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1?
NASDAQ · 2d ago
Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofA
BofA Securities upgraded Integer Holdings Corporation from Neutral to Buy. The analyst cites the anticipated growth in pulsed field ablation (PFA) for treating atrial fibrillation. PFA sales are expected to surge from $100 million in 2023 to over $2 billion in 2025.
Benzinga · 3d ago
Boston Scientific Is Maintained at Outperform by RBC Capital
Dow Jones · 3d ago
Boston Scientific Price Target Raised to $78.00/Share From $70.00 by RBC Capital
Dow Jones · 3d ago
RBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $78
Benzinga · 3d ago
BUZZ-Truist bets on a 'beat & raise' Q1 for some med-tech players
Brokerage Truist Securities expects Q1 results beat and forecast raises for medical device makers Boston Scientific Corp BSX.N and Intuitive Surgical. Truist believes medical-technology sector will see rising earnings this quarter. Medical device makers have been benefitting from a resurgence in demand for joint replacements.
Reuters · 3d ago
Weekly Report: what happened at BSX last week (0408-0412)?
Weekly Report · 3d ago
BOSTON SCIENTIFIC CORP <BSX.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $79 FROM $73
Reuters · 3d ago
BOSTON SCIENTIFIC CORP <BSX.N>: RBC RAISES TARGET PRICE TO $78 FROM $70
Reuters · 3d ago
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time BSX stock news. You can receive the latest news about Boston Scien Cp through multiple platforms. This information may help you make smarter investment decisions.
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.